The FDA is not aware of any basis for compounding using the salt forms that would meet the FD&C Act conditions for types of active ingredients that can be used in compounding.
Importantly, ketogenic metabolic therapy should not be considered a stand-alone intervention in the management of bipolar disorder with metabolic syndrome
Subsequent biochemistry assays confirmed that DMF significantly increases GSH, cystathionine, and cysteine levels, along with moderately increased homocysteine levels (Fig
Determine the ideal treatment method with your provider, tailored to your personal requirements, insurance provisions, and lifestyle preferences
Correspondingly, this implies that the cardiac benefits of GLP-1 agonism may arise in part from this metabolic support
(5.1) Never share a BYETTA pen between patients, even if the needle is changed